clinicalomicsprowebdirectory
News
Topics
Precision Medicine
Translational Research
Molecular Dx
Informatics
Oncology
Patient Care
New Products
Magazine
Marketplace
Multimedia
Webinars
eBooks
Subscribe
Create a Free Account
Log In
Get Clinical OMICs Magazine
Get Clinical OMICs eNewsletters
Get the Clinical OMICs Mobile App
Get Clinical OMICs News from Alexa
Search
Advertise
Magazine Advertising
Website Banner Advertising
eNewsletter Advertising
Lead Generation Campaigns
Email Nurture Campaigns
Custom Content Solutions
About Us
Contact Us
Mary Ann Liebert Publishers
Create a Free Account
Log In
Clinical OMICs – Molecular Diagnostics in Precision Medicine
News
News & Features
Genes Linked to Down Syndrome-Related Abnormalities May Reduce Cancer Risk
Coronavirus
NIH Launches Remdesivir Plus Interferon Beta-1a Trial for COVID-19 Treatment
Translational Research
The Gut Microbiome Helps Determine B Cell and Antibody Repertoire
Precision Medicine
TRACK Study Seeks to Develop Precision Medicine Approaches for Rare Cancers
Molecular Dx
AI Predicts Patient Phenotypes that Will Develop Drug Resistance
Topics
All
Precision Medicine
Translational Research
Molecular Dx
Informatics
Oncology
Patient Care
New Products
Coronavirus
NIH Launches Remdesivir Plus Interferon Beta-1a Trial for COVID-19 Treatment
Translational Research
The Gut Microbiome Helps Determine B Cell and Antibody Repertoire
Precision Medicine
TRACK Study Seeks to Develop Precision Medicine Approaches for Rare Cancers
Molecular Dx
AI Predicts Patient Phenotypes that Will Develop Drug Resistance
Magazine
Magazine
Clinical OMICs Magazine Volume 7, Issue No. 3
Magazine
Clinical OMICs Magazine Volume 7, Issue No. 2
Magazine
Clinical OMICs Magazine Volume 7, Issue No. 1
Magazine
Clinical OMICs Magazine Volume 6, Issue No. 6
Magazine
Clinical OMICs Magazine Volume 6, Issue No. 5
Marketplace
Multimedia
All
Webinars
eBooks
Multimedia
Navigating Complexity in Oncology Cell and Gene Therapy Clinical Trials
Multimedia
Sequencing Controls Improve Confidence in NGS Patient Results
Bioinformatics
Advanced AI Technology for Clinical Genomic Support Across All Stages of…
Precision Medicine
RNA, Data Science, and the Future of Precision Medicine
Subscribe
Create a Free Account
Log In
Get Clinical OMICs Magazine
Get Clinical OMICs eNewsletters
Get the Clinical OMICs Mobile App
Get Clinical OMICs News from Alexa
Home
Precision Medicine
Precision Medicine
Precision Medicine
7 days popular
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Precision Medicine
Six Precision Medicine Companies Making Their Mark in 2020
June 15, 2020
Precision Medicine
RNA, Data Science, and the Future of Precision Medicine
July 23, 2020
Precision Medicine
TRACK Study Seeks to Develop Precision Medicine Approaches for Rare Cancers
August 6, 2020
Precision Medicine
Custom Mouse Models Could Help Personalize Cancer Therapy
July 27, 2020
Precision Medicine
Human Longevity Publishes Disease Risk, Early Detection Data
February 3, 2020
Precision Medicine
LAM Gets FDA Breakthrough Designation for Liver Cancer Liquid Biopsy
September 4, 2019
Precision Medicine
DNAnexus Wins Five-Year, $20M Contract to Power precisionFDA Platform
December 6, 2019
Precision Medicine
Roche, Blueprint Medicines Target RET-Altered Cancers with $1.7B Partnership
July 14, 2020
Precision Medicine
Treading with Caution: PGx Test Developers Pursue Dialogue as FDA Maintains...
November 7, 2019
Precision Medicine
Genome Medical Raises $14M in Series B Financing
July 1, 2020
1
2
3
...
25
Page 1 of 25
Scroll Up
We use cookies to give you a better experience on clinicalomics.com. By continuing to use our site, you are agreeing to the use of cookies as set in our
privacy policy.
Got it!
Edit with Live CSS
![Tumor profiling assays of Foundation Medicine and Caris Life Sciences will identify abnormalities qualifying a patient for personalized cancer treatment through NCI-MATCH. [Royalty Stock Photo/Shutterstock]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1125-218x150.jpeg "TRACK Study Seeks to Develop Precision Medicine Approaches for Rare Cancers")
![Tumor profiling assays of Foundation Medicine and Caris Life Sciences will identify abnormalities qualifying a patient for personalized cancer treatment through NCI-MATCH. [Royalty Stock Photo/Shutterstock]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1125-324x160.jpeg "TRACK Study Seeks to Develop Precision Medicine Approaches for Rare Cancers")
![Epic Sciences said today its liquid biopsy blood test showed in a study that it can help physicians select prostate cancer patients who are likely to benefit from a Pfizer prostate-specific membrane antigen (PSMA)-targeted therapy candidate known as BIND-014 before the start of treatment. [Source: © Alex Tihonov/Fotolia]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1907-324x160.jpeg "LAM Gets FDA Breakthrough Designation for Liver Cancer Liquid Biopsy")
